A year-end review of some of the new cancer treatments, exciting breakthroughs, and insights into cancer's development that emerged...
The American Association for Cancer Research (AACR) is proud to support the Scientist↔Survivor Program (SSP), which provides cancer survivors...
Assessing new anticancer therapeutics in clinical trials is a vital step in evaluating the toxicity and efficacy of treatment...
Skin cancer is the most commonly diagnosed cancer in the United States. Every year, about 5 million Americans are...
Multiple myeloma arises in immune cells called plasma cells. It is one of the most commonly diagnosed hematological malignancies...
Although liver cancer isn’t as prevalent as lung cancer or breast cancer, this cancer is now the fastest-increasing cause...
On May 4, the U.S. Food and Drug Administration (FDA) approved a combination of molecularly targeted therapeutics for the...
While immunotherapy may be the latest tool in the treatment armamentarium for cancer, many ongoing clinical trials are assessing...
Norman E. “Ned” Sharpless, MD, who became director of the National Cancer Institute in October 2017, recently unveiled areas...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved expanding the use of the immunotherapeutic tisagenlecleucel (Kymriah)...
This was another spectacular year for the AACR Annual Meeting with its record-breaking attendance of more than 22,500. From...